Production (Stage)
Translational Development Acquisition Corp.
TDAC
$10.31
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 160.42% | 117.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 160.42% | 117.62% | |||
| Operating Income | -160.42% | -117.62% | |||
| Income Before Tax | 18,638.75% | 86.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18,638.75% | 86.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18,638.75% | 86.95% | |||
| EBIT | -160.42% | -117.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 4,613.33% | 90.07% | |||
| Normalized Basic EPS | 4,800.00% | 90.53% | |||
| EPS Diluted | 4,613.33% | 90.07% | |||
| Normalized Diluted EPS | 4,800.00% | 90.53% | |||
| Average Basic Shares Outstanding | 304.20% | 33.82% | |||
| Average Diluted Shares Outstanding | 304.20% | 33.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||